Antibody response, neutralizing potency, and transplacental antibody transfer following SARS-CoV-2 infection versus mRNA-1273, BNT162b2 COVID-19 vaccination in pregnancy
© 2023 International Federation of Gynecology and Obstetrics..
OBJECTIVE: To improve our understanding of the immune response, including the neutralization antibody response, following COVID-19 vaccination in pregnancy.
METHODS: This was a prospective cohort study comprising patients with PCR-confirmed SARS-CoV-2 infection and patients who received both doses of mRNA COVID-19 vaccine (mRNA-1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, GA, USA. Maternal blood and cord blood at delivery were assayed for anti-receptor binding domain (RBD) IgG, IgA and IgM, and neutralizing antibody. The detection of antibodies, titers, and maternal to fetal transfer ratios were compared.
RESULTS: Nearly all patients had detectable RBD-binding IgG in maternal and cord samples. The vaccinated versus infected cohort had a significantly greater proportion of cord samples with detectable neutralizing antibody (94% vs. 28%, P < 0.001) and significantly higher transfer ratios for RBD-specific IgG and neutralizing antibodies with a transfer efficiency of 105% (vs. 80%, P < 0.001) and 110% (vs. 90%, P < 0.001), respectively. There was a significant linear decline in maternal and cord blood RBD-specific IgG and neutralizing antibody titers as time from vaccination to delivery increased.
CONCLUSIONS: Those who receive the mRNA COVID-19 vaccine mount an immune response that is equivalent to-if not greater than-those naturally infected by SARS-CoV-2 during pregnancy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics - 162(2023), 1 vom: 24. Juli, Seite 154-162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dude, Carolynn M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 19.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijgo.14648 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351094725 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351094725 | ||
| 003 | DE-627 | ||
| 005 | 20231226050520.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijgo.14648 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351094725 | ||
| 035 | |a (NLM)36598270 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dude, Carolynn M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody response, neutralizing potency, and transplacental antibody transfer following SARS-CoV-2 infection versus mRNA-1273, BNT162b2 COVID-19 vaccination in pregnancy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 19.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 International Federation of Gynecology and Obstetrics. | ||
| 520 | |a OBJECTIVE: To improve our understanding of the immune response, including the neutralization antibody response, following COVID-19 vaccination in pregnancy | ||
| 520 | |a METHODS: This was a prospective cohort study comprising patients with PCR-confirmed SARS-CoV-2 infection and patients who received both doses of mRNA COVID-19 vaccine (mRNA-1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, GA, USA. Maternal blood and cord blood at delivery were assayed for anti-receptor binding domain (RBD) IgG, IgA and IgM, and neutralizing antibody. The detection of antibodies, titers, and maternal to fetal transfer ratios were compared | ||
| 520 | |a RESULTS: Nearly all patients had detectable RBD-binding IgG in maternal and cord samples. The vaccinated versus infected cohort had a significantly greater proportion of cord samples with detectable neutralizing antibody (94% vs. 28%, P < 0.001) and significantly higher transfer ratios for RBD-specific IgG and neutralizing antibodies with a transfer efficiency of 105% (vs. 80%, P < 0.001) and 110% (vs. 90%, P < 0.001), respectively. There was a significant linear decline in maternal and cord blood RBD-specific IgG and neutralizing antibody titers as time from vaccination to delivery increased | ||
| 520 | |a CONCLUSIONS: Those who receive the mRNA COVID-19 vaccine mount an immune response that is equivalent to-if not greater than-those naturally infected by SARS-CoV-2 during pregnancy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a reproductive immunity | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Joseph, Naima T |e verfasserin |4 aut | |
| 700 | 1 | |a Forrest, Alexandra D |e verfasserin |4 aut | |
| 700 | 1 | |a Verkerke, Hans P |e verfasserin |4 aut | |
| 700 | 1 | |a Cheedarla, Narayanaiah |e verfasserin |4 aut | |
| 700 | 1 | |a Govindaraj, Sakthivel |e verfasserin |4 aut | |
| 700 | 1 | |a Irby, Les'Shon S |e verfasserin |4 aut | |
| 700 | 1 | |a Easley, Kirk A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Alicia K |e verfasserin |4 aut | |
| 700 | 1 | |a Stowell, Sean R |e verfasserin |4 aut | |
| 700 | 1 | |a Neish, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Amara, Rama Rao |e verfasserin |4 aut | |
| 700 | 1 | |a Jamieson, Denise J |e verfasserin |4 aut | |
| 700 | 1 | |a Dunlop, Anne L |e verfasserin |4 aut | |
| 700 | 1 | |a Badell, Martina L |e verfasserin |4 aut | |
| 700 | 1 | |a Velu, Vijayakumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics |d 1973 |g 162(2023), 1 vom: 24. Juli, Seite 154-162 |w (DE-627)NLM000003336 |x 1879-3479 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2023 |g number:1 |g day:24 |g month:07 |g pages:154-162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijgo.14648 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2023 |e 1 |b 24 |c 07 |h 154-162 | ||